UNSPSC 51141592: Eslicarbazepine acetate

This classification denotes an anticonvulsant agent C17H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BEA68ZVB2K, chemically known as (10s)-5-carbamoyl-10,11-dihydro-5h-dibenzo(b,f)azepin-10-yl acetate, but more generally known as eslicarbazepine acetate, which bears US NIH Compound Identifier 179344. European Medicines Agency schedules Eslicarbazepine acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30424.

Most nations, for tariff and trade purposes, schedule eslicarbazepine acetate under HS 29339930 and SITC 51577. As of Q4 2014, ESLICARBAZEPINE ACETATE remains US FDA's Preferred Term for this commodity. Eslicarbazepine acetate bears US NLM identifiers UMLS ID C2725262 and NCI Concept Code C83697. SMILES: CC(=O)O[C@H]1CC2CCCCC2N(C3C1CCCC3)C(=O)N.

UNSPSC 51141592 Eslicarbazepine acetate is a Commodity code that encompasses individual pharmaceutical products supplied to state and local government health systems, emergency management agencies, and cooperative purchasing entities. Recent state and local solicitations under this code show activity in naloxone procurement, generic multi-source pharmaceutical distribution agreements, and therapeutic pharmacy initiatives serving health departments, county emergency response programs, and multistate cooperative purchasing organizations. The issuing bodies include county health departments, state health and human services commissions, and regional cooperative purchasing alliances serving multiple jurisdictions. Work solicited ranges from direct procurement of specific quantities of finished pharmaceuticals with scheduled quarterly deliveries to state and local facilities, to establishment of master supply agreements with authorized wholesalers for generic drugs and OTC products distributed across participating state agencies and municipalities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly delivery to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, and contract awards to become effective July 1, 2026. The Minnesota solicitation requires vendors to maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and mandates compliance with cGMP, DSCSA, FDA requirements, and insurance coverage including $5,000,000 commercial general liability per occurrence.